Feed CODX
CO

Co-Diagnostics, Inc.

CODX · NASDAQ

$1.01 +2.03% (+$0.02)
1M -17.21%
Market Cap $1.13M
P/E Ratio -
Div. Yield -
ROE 210.99%

Bulios Fair Price

$1.44

42.6% upside

Trenutna cena

$1.01

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica CODX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
94 /100
Cheap
P/S 1.56x
P/B 0.09x
P/E N/A
Growth
0 /100
Declining
Rev. growth 73.70%
Book val. growth 43.52%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 8.07%
Net margin 6,523.04%
FCF margin 3,808.02%
Quality
1 /100
Poor
ROIC 200.40%
ROE 210.99%
Asset turnover 0.04x
Debt
97 /100
Low
Debt/Equity 0.14x
Current ratio 1.81x
Int. coverage N/A
Stability
15 /100
Unstable
Beta 2.86x
Rev. volatility 22.93%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CODX
Online

O podjetju

Co-Diagnostics, Inc. (CODX) is an American biotechnology company specializing in the development and manufacturing of diagnostic tests and reagent kits for the detection of various infectious diseases. The company focuses on innovative molecular diagnostic technologies that enable rapid and accurate determination of pathogens in patient samples. Its diagnostic tools are applied in the detection of viral, bacterial, and parasitic infections, serving both as diagnostic and monitoring solutions for diseases. With its advanced diagnostic technologies, Co-Diagnostics can contribute to improving healthcare and reducing the spread of infectious diseases. The company continually emphasizes research and development of new diagnostic tests to meet the needs of the medical community. Co-Diagnostics, Inc. (CODX) shares may be an attractive investment opportunity for investors interested in the healthcare sector and seeking an investment in a company dedicated to innovative diagnostic technologies.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Dwight Egan

Employees

115

Headquarters

Salt Lake City

Prihajajoči dogodki

16 NOV.

Earnings

Upcoming earnings report

55d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.